Alyeska Investment Group
EPRX

Alyeska Investment Group’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Alyeska Investment Group’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Hold
375,000
– – 0.01% 560
2026
Q1 		$2.71M Buy
+375,000
New +$3.02M 0.01% 534
2025
Q4 		– Sell
-250,000
Closed -$1.48M – 754
2025
Q3 		$1.48M Buy
+250,000
New +$1.36M ﹤0.01% 522

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Alyeska Investment Group's EPRX Position: Q2 2026 in Review

Alyeska Investment Group held its Eupraxia Pharmaceuticals (EPRX) position steady in Q2 2026 at 375,000 shares worth $2.48M. The position accounts for 0.01% of the portfolio, ranked #560.

Alyeska Investment Group first reported a position in EPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.71M in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Alyeska Investment Group held 375,000 shares of Eupraxia Pharmaceuticals worth $2.48M as of Q2 2026.
  • Alyeska Investment Group left its Eupraxia Pharmaceuticals share count unchanged in Q2 2026.
  • Eupraxia Pharmaceuticals made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #560 holding.
  • Alyeska Investment Group first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Alyeska Investment Group's Eupraxia Pharmaceuticals position peaked at $2.71M in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.